ArticleHepatology communications2025
Feasible and acceptable social drivers of health screening among patients with chronic liver disease.
Article in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Health advocates to address social adversity in pediatric liver transplantation: A clinical trial.Hepatology communications · 2026Trial
- High mortality at safety-net hospitals for patients with cirrhosis.Hepatology communications · 2026Article
- Reply: High mortality at safety-net hospitals for patients with cirrhosis.Hepatology communications · 2026Article
- Social needs screening in hepatology clinic: a qualitative study of patient experience.BMC gastroenterology · 2026Article
- Food Insecurity and Chronic Liver and Gastrointestinal Conditions: A Systematic Review of Prevalence and Clinical Outcomes.Gastro hep advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSocial drivers of health (SDoH) contribute to health disparities among patients with chronic liver disease (CLD). Little is known about the feasibility and acceptability of SDoH screening in hepatology clinics. This study aimed to define SDoH prevalence among CLD patients, identify a feasible and acceptable screening approach, and assess the convergent validity of a locally developed screener.
methodsAmong adult patients with CLD receiving care in hepatology clinics, 2 SDoH screeners were administered to eligible participants: (1) default electronic medical record (EMR) questions and (2) Screener for Intensifying Community Referrals for Health (SINCERE). The primary outcomes were (1) prevalence of SDoH, (2) SDoH screening feasibility and acceptability, and (3) factors associated with screening acceptability. As a secondary outcome, the convergent validity of SINCERE to EMR was assessed.
resultsAmong 250 participants, the mean age was 56 years, 56% were women, 22% were Hispanic, 7% were American Indian/Alaska Native, 58% had cirrhosis, 29% completed high school or less, 22% were unemployed/disabled, and 29% had an annual income <$35,000. Based on SINCERE, 26% had food insecurity, 8% transportation needs, 43% financial strain, 5% lack of social support, and 24% housing instability. Most respondents (69%) were comfortable or very comfortable completing SDoH screening. Using the McNemar test, there were statistically significant differences between screeners for financial strain and housing instability.
conclusionsAmong CLD patients at our center, SDoH were prevalent, and screening within the hepatology clinic was feasible and acceptable. To detect social needs, SINCERE, a locally developed screener, had overall acceptable convergent validity. These data support SDoH screening in hepatology clinics. Future multicenter studies evaluating the effective implementation of SDoH screening for CLD patients, including contextualized care plans and connection to available resources, should be conducted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.